Multiple Myeloma Coverage from Every Angle

Efstathios Kastritis, MD: A New Standard of Care for Amyloidosis in Multiple Myeloma?

Posted: Wednesday, July 7, 2021

Efstathios Kastritis, MD, of the University of Athens, discusses updated findings from the phase III ANDROMEDA study and the clinical implications of supplementing the current standard of care for light chain amyloidosis (bortezomib, cyclophosphamide, and dexamethasone) with daratumumab.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.